Sorry, we need to confirm your details before you can access this content.
If you have just signed up to OnMedica, you are seeing this message because we couldn’t automatically verify that you are a practising doctor in the UK. Please check your email inbox as we may need a few more details to validate your OnMedica membership. If you haven’t received an email from us or you need assistance, please contact firstname.lastname@example.org.
New NICE draft guidance means that close to one third of patients with hereditary angioedema in England will be eligible for berotralstat, the first oral treatment for this condition to be made available on the NHS.